Preterm delivery (PTD) is the best example: it is defined as delivery occurring before 37 completed gestational weeks and is the major cause of neonatal morbidity and mortality in developed countries [3]. It is a syndrome initiated by several causes, representing either a breakdown in the mechanisms responsible for maintaining uterine quiescence or an overwhelming of the normal parturition cascade: (i) the uterine pathway including myometrial contractility, cervical ripening and decidua/membrane activation [4] and (ii) the endocrine pathway regulating maternal/fetal mechanisms leading to labor and delivery [5]. The maternal/fetal hypothalamus pituitary adrenal (HPA) axis contains all the stress hormones corticotropin-releasing hormone (CRH), ACTH and cortisol and during pregnancy, CRH and ACTH also are secreted by placenta [6]. They regulate several biological functions including the secretion of steroid hormones such as dehydroepiandrosteronesulfate (DHEA-S) and estriol.

Stress of delivery is associated with higher maternal levels of CRH, ACTH, cortisol, DHEAS-S and estriol, thus supporting the relevance of HPA axis hormones in the adaptive response of mother and fetus [7]. The same event has been shown in PTD, resulting very high concentration of HPA axis hormones in maternal plasma [7]. CRH and estriol maternal levels have also been found to be high prior the onset of PTD and proposed as possible predictive markers [8]. This is of high clinical relevance since the tocolitic agents are poorly effective in the treatment of PTD [8] while new therapeutic strategies may be developed when women at risk are identified. The evolution of maternal serum CRH concentrations parallels the CRH curve of normal pregnancy but the level is displaced upward [9]. This discrimination is detectable before any clinical manifestation of uterine contractility, a fact that prompted the design of controlled studies focusing on the value of second-trimester CRH levels in predicting preterm birth. Maternal plasma levels of CRH are significantly elevated at as early as 18 to 20 weeks' gestation in women who are subsequently delivered preterm. It was shown that changes in CRH between 18 to 20 weeks' gestation and 28 to 30 weeks' gestation are associated with maternal age and stress level at 18 to 20 weeks' gestation [10]. Others studies are confirming a possible value of CRH as predictive marker of PTD [11-13]. Maternal plasma CRH beyond 28 weeks is an accurate biomarker in predicting preterm birth within 48 hours [14]. Although CRH maternal levels increase at mid trimester there are not sufficient data supporting the routine clinical use of plasma CRH as a predictor of preterm labor. A previous study following a low-risk women starting at 15-20 weeks of gestation demonstrates that CRH levels were higher in the group who delivered before 34 weeks but not in the whole preterm group [15].

Moreover, it is shown that a single measurement of plasma CRH, toward the end of the second trimester, may identify a group at risk for preterm delivery, but over 50% of such deliveries will be unpredicted [16] Several studies evaluated the ability of maternal estriol to predict preterm delivery in populations of asymptomatic or symptomatic women. Estriol originates almost exclusively from fetal DHEA-S [17]. Thus, estriol in the mother serves as a marker of the activity of the fetal adrenal gland. Saliva estriol levels reflect the concentrations of free, unconjugated estriol in plasma and therefore correspond to the biologically active fraction of the circulating hormone [1819]. Several studies shown that a single salivary estriol value higher than 2.1 ng/ml between 21 and 25 weeks in asymptomatic women is associated with an increased risk of preterm birth, and in this regard the estriol measurement achieves greater sensitivity than a standard clinical test [1819]. A potential contribution of salivary estriol measurement comes from negative tests in high-risk populations. Among patients considered at high-risk, two consecutive weekly estriol tests in the normal range suggest that the patient is likely to proceed to term, either without threatened preterm labor or by responding to tocolysis [19 20]. In symptomatic women, salivary estriol is associated with an increased risk of delivery within two weeks, but its predictive power is modest [20 21]. Maternal serum estriol levels accurately reflect activation of the fetal HPA axis, which occurs before the onset of premature uterine contractions [17]. Recent studies demonstrates that two weeks before PTD there is critically altered P/E3 and E3/E2 ratios in maternal plasma that create an estrogenic environment for the onset of labor [21 18].

Recently, a new member of CRH family, urocortin (Ucn) has been described to be involved in the mechanisms leading PTD. Maternal plasma Ucn levels are significantly higher at term and preterm labor compared with those after elective caesarean section [22]. Moreover, fetal Ucn concentrations are higher than maternal concentrations, suggesting that the fetus is a major source of Ucn. Maternal plasma Ucn levels are increased in patients with threatened preterm labor who delivered before 34 completed weeks of pregnancy[23]. At the second trimester amniocentesis, in healthy pregnancies, amniotic fluid concentration of Ucn are low in women later undergoing to PTD [24].
On the basis of these evidences, it is suggested that fetus, through Ucn, placenta, through CRH secretion and estriol, deriving from feto-placental unit,may exert their biologic roles at the time of delivery, emphasizing the possible enhancement in the mechanism of PTD. In conclusion, a few evidences are available to recommend the routine use of hormone tests to predict PTD but, their clinical usefulness may enhance the sensitivity of the risk assessment, how only based on clinical and ultrasound examination. Cervicovaginal fetal fibronectin [25] and transvaginal sonographic cervical length measurements [26] represent a useful factors predictors of PTD in clinical practice, specially when their use is combined [27]. Therefore, the gool will be to combine these multiple approaches in a predictive test for PTD.

References

1. Petraglia F, Florio P, Nappi C, Genazzani AR Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Endocr Rev 1996; 17:156–186.
2. Grammatopoulos DK, Hillhouse EW Role of corticotropinreleasing hormone in onset of labour. Lancet 1999; 354:1546–1549.
3. Iams J. Prevention of preterm birth. N Engl J Med. 1998;338:54-6.
4. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome.BJOG 2006;113.
5. Gibb W, Challis JR. Mechanisms of term and preterm birth. J Obstet Gynaecol Can 2002;24:874–83.
6. Petraglia F, Sawchenko PE, Rivier J, Vale W. Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta. Nature. 1987 26;328: 717-9.
7. Smith R, Nicholson RC. Corticotrophin releasing hormone and the timing of birth. Front Biosci. 2007 ;12:912-8.
8. Smith V, Devane D, Begley CM, Clarke M, Higgins S. A systematic review and quality assessment of systematic reviews of randomised trials of interventions for preventing and treating preterm birth. Eur J Obstet Gynecol Reprod Biol. 2009;142:3-11.
9. Lockwood CJ. The diagnosis of preterm labor and the prediction of PTD. Clin Obstet Gynecol 1995; 38: 675–687.
10. McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R. A placental clock controlling the length of human pregnancy. Nat Med. 1995;1:460-3.
11. C, Ramirez MM, Watson L, Brinkman E, Bocking AD, Challis JR. Maternal corticotropin-releasing hormone is increased with impending preterm birth. J Clin Endocrinol Metab 1998; 83:1585–1591.
12. Challis JR. CRH, a placental clock and preterm labour.Nat Med. 1995;1:416
13. . Berkowitz GS, Lapinski RH, Lockwood CJ, Florio P, Blackmore-Prince C, Petraglia F. Corticotropin-releasing factor and its binding protein: maternal serum levels in term and preterm deliveries. 1996 Am J Obstet Gynecol 174:1477–1483.
14. Hill JL, Campbell MK, Zou GY, Challis JR, Reid G, Chisaka H, Bocking AD. Prediction of preterm birth in symptomatic women using decision tree modeling for biomarkers. Am J Obstet Gynecol. 2008;198:468.
15. Leung TN, Chung TK, Madsen G, McLean M, Chang AM, Smith R Elevated mid-trimester maternal corticotrophin-releasing hormone levels in pregnancies that delivered before 34 weeks. Br J Obstet Gynaecol 1999; 106:1041-1046
16. Inder WJ, Prickett TC, Ellis MJ, Hull L, Reid R, Benny PS, Livesey JH, Donald RA J Clin Endocrinol Metab. The utility of plasma CRH as a predictor of preterm delivery.. 2001; 86: 5706-10.
17. Goodwin TM. A role for estriol in human labor, term and preterm. Am J Obstet Gynecol, 1999; 180: S208-13.
18. Darne J, McGarrigle HH, Lachelin GC. Increased saliva oestriol to progesterone ratio before preterm delivery: a possible predictor for preterm labor? Br Med J 1987; 294:270-272.
19. Heine RP, McGregor JA, Dullien VK. Accuracy of salivary estriol testing compared to traditional risk factor assessment in predicting preterm birth. Am J Obstet Gynecol 1999; 180:S214-S218.
20. Heine RP, McGregor JA, Goodwin TM, Artal R, Hayashi RH, Robertson PA, Varner MW. Serial salivary estriol to detect an increased risk of preterm birth. Obstet Gynecol 2000; 96:490-497.
21. Smith R, Smith JI, Shen X, Engel PJ, Bowman ME, McGrath SA, Bisits AM, McElduff P, Giles WB, Smith DW. Patterns of plasma corticotropin-releasing hormone, progesterone, estradiol, and estriol change and the onset of human labor. J Clin Endocrinol Metab. 2009;94: 2066-74.
22. Florio P, Torricelli M, Galleri L, De Falco G, Leucci E, Calonaci G, Picciolini E, Ambrosini G, Linton EA, Petraglia F High fetal urocortin levels at term and preterm labor. JCE&Metab 2005; 90:5361-5365.
23. Florio P, Linton EA, Torricelli M, Faldini E, Reis FM, Imperatore A, Calonaci G, Picciolini E, Petraglia F. Prediction of Preterm Delivery Based on Maternal Plasma Urocortin JCE& Metabolism 2007; 92:4734-4737.
24. Torricelli M, Voltolini C, Galleri L, Biliotti G, Giovannelli A, De Bonis M, De Pascalis F, Centini G, Petraglia F. Amniotic fluid urocortin, CRF, oestriol, dehydroepiandrosterone sulfate and cortisol concentrations at mid-trimester: putative relationship with preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2009;146:169-73.
25. Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991;325:669-674
26. Mella MT, Berghella V. Prediction of preterm birth: cervical sonography. Semin Perinatol. 2009;33:317-24.
27. Smith V, Devane D, Begley CM, Clarke M, Higgins S. A systematic review and quality assessment of systematic reviews of fetal fibronectin and transvaginal length for predicting preterm birth. Eur J Obstet Gynecol Reprod Biol. 2007;133:134-42.